Weight loss craze squeezes diabetes drug supply
Rising demand is tightening supply of diabetes drugs, reducing availability for patients.
Source →The trace
How it reaches your house.
Starting from GLP-1 drugs (Ozempic, Wegovy, Mounjaro), we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Insulin →Stands to benefitWeight-loss drugs
The cited source says insulin production is being slashed in favour of more lucrative weight-loss drugs, so they benefit from the capacity shift.
“Pharmaceutical companies are slashing insulin production in favour of more lucrative weight-loss drugs.”
96% confidenceCited →GLP-1 drugs (Ozempic, Wegovy, Mounjaro) →Shortage riskGLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type)
Ozempic and Wegovy rely heavily on this critical peptide API, so a demand-driven squeeze on the finished GLP-1 drugs tightens upstream semaglutide/liraglutide API availability.
90% confidenceGLP-1 drugs (Ozempic, Wegovy, Mounjaro) →Shortage riskGLP-1/GIP Dual-Agonist Peptide API (Tirzepatide)
Mounjaro depends directly on tirzepatide API, so stronger demand for the finished drug can translate into upstream API scarcity.
89% confidenceGLP-1 drugs (Ozempic, Wegovy, Mounjaro) →Prices riseGLP-1 Disposable Injection Pen / Auto-Injector
Higher demand for injectable GLP-1 drugs pushes more volume through pen auto-injector supply, raising component costs.
80% confidenceInsulin →Prices easeRecombinant Insulin API (Bulk Drug Substance)
If insulin production is being cut back, demand for the dedicated recombinant insulin bulk drug substance falls sharply, pressuring its price downward.
80% confidenceGLP-1 drugs (Ozempic, Wegovy, Mounjaro) →Prices riseReady-to-Use Type I Borosilicate Glass Cartridge (Pen)
The pen-based GLP-1 format depends on ready-to-use cartridges, so tighter drug supply and replenishment pressure lift cartridge demand and prices.
76% confidenceHop 2
GLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type) →Shortage riskGLP-1 drugs (Ozempic, Wegovy, Mounjaro)
This peptide API is a critical input to the finished GLP-1 drugs, so a squeeze here directly cuts finished-drug availability.
98% confidenceGLP-1/GIP Dual-Agonist Peptide API (Tirzepatide) →Shortage riskGLP-1 drugs (Ozempic, Wegovy, Mounjaro)
Tirzepatide API is a critical, high-dependency input for these GLP-1 drugs, so a tighter API supply directly reduces finished-drug availability.
97% confidenceRecombinant Insulin API (Bulk Drug Substance) →Shortage riskHop 3
Novo Nordisk →Shortage riskGLP-1 Receptor Agonist Peptide API (Semaglutide / Liraglutide Type)
Novo Nordisk’s GLP-1 franchise is overwhelmingly dependent on this near-sole-source API (95% share, sole qualified supplier, 60-month replacement lead time), so the demand surge tightens this input and makes it harder to source.
94% confidenceSCHOTT Pharma AG & Co. KGaA →Shortage riskType I borosilicate glass vials
Rising demand for SCHOTT's cartridge output would tighten supply of this vial input, and the 24-month replacement lead time plus low substitutability make the constraint substantial.
82% confidenceBachem Holding AG →Stands to benefit
Where it lands
What you buy, and what you own.
Goods you buy
GLP-1 drugs (Ozempic, Wegovy, Mounjaro) · Insulin
In the MyPRIA app, this is checked against your own holdings.